Targeting lung-derived proteins

This research team aims to understand the interactions between CD44+ breast cancer cells and CD44-interacting proteins produced by the lung microenvironment in order to determine how this helps migration and growth in the lung as part of the metastatic process. We are investigating whether we can use an inhaled drug delivery approach to directly inhibit CD44-interacting proteins in the lung as an effective strategy for reducing breast cancer metastasis as well as toxic side effects. By gaining a greater understanding of the underlying biology and therapeutic potential of lung-derived factors in breast cancer metastasis, we have the potential to positively impact breast cancer patient survival in the future.

Continue Reading

End of content

No more pages to load

Close Menu